OVARIAN CANCER and US: lymphadenectomy

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label lymphadenectomy. Show all posts
Showing posts with label lymphadenectomy. Show all posts

Monday, May 14, 2012

Correspondence: re - Intra-operative frozen section analysis for suspected early-stage ovarian cancer - Twigg - 2012 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library



Intra-operative frozen section analysis for suspected early-stage ovarian cancer - Twigg - 2012 - BJOG: An International Journal of Obstetrics & Gynaecology

Volume 119, Issue 7, page 896, June 2012
Sir,
We read with interest the article by Cross et al.1 on the use of intra-operative frozen section for suspected early ovarian cancer. We would like to commend the authors for their work in providing these data and we recognise the need for mechanisms that can be used to address the National Institute for Health and Clinical Excellence (NICE) Guidelines CG122, which recommend assessment of the para-aortic lymph nodes in women with early ovarian cancer.2
However, there are a number of areas of practice that we feel need to be examined further before frozen section procedures can be used to alter the management of women with suspected early-stage ovarian cancer.
First, we are perplexed that the authors deemed it necessary to undertake para-aortic lymphadenectomy for women with borderline ovarian tumours. These are by nature an unpredictable class of tumour with mostly good outcomes and little in the way of nonsurgical treatment options when there is disseminated disease. Further, they are usually early-stage tumours and so the utility of a para-aortic lymph node dissection is questionable. If the authors had described the rate of disease in lymph nodes and the difference in outcome this provided for the woman with positive nodes their data would lend stronger support for more widespread implementation.
Accepting this and examining the authors data for ‘all comers’ (Table 1) we calculate that 28.8% (415) of women had an appropriate para-aortic lymph node dissection on the basis of the frozen section prediction, which represents the real-world scenario for the gynaecological oncology surgeon waiting in theatre for a frozen section analysis to be phoned back.
If the authors changed their protocol to only using dissection in women with malignancy on frozen section, 63.8% (918) of women would appropriately not undergo a para-aortic dissection. The total number of women correctly triaged by frozen section analysis would be 92.6%. Of the remainder, 7% would not undergo a para-aortic dissection that should and 0.35% would have a dissection they do not need. Such a protocol change compares with the authors’ figures who, when including a policy of para-aortic dissection for borderline tumours on frozen section, overtreated 8% of the women and undertreated 1.3%.
The answer to deciding which strategy one would wish to take up must come down to the differences in outcome for these women, defined by morbidity and mortality comparisons from overtreatment or undertreatment by surgery or chemotherapy, respectively, and any subsequent influence this has on overall survival. Unfortunately the authors do not provide this information, and only allude to data in preparation that indicate their ability to increase the stage of a woman’s disease. However, this figure can be calculated from their data in Table 1 to equate to 82 women (5.7%) who had a frozen section showing borderline disease but whose final paraffin section report showed a malignancy. Until other centres can validate their techniques and such practice can be shown to translate into a survival benefit for women, it is unlikely that their data will change surgical practice in women with early ovarian cancer.

References

  • 1
    Cross P, Naik R, Patel A, Nayar A, Hemming J, Williamson S, et al. Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG 2012;119:194201.
  • 2
    National Institute for Health and Clinical Excellence. The recognition and initial management of ovarian cancer. [http://www.nice.org.uk/CG122]. Accessed 20 January 2012. 

Wednesday, May 09, 2012

paywalled: Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?



Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients? 

Abstract

Aim:  The effect of systematic retroperitoneal lymphadenectomy (SRL) remains controversial in patients with advanced epithelial ovarian cancer (aEOC) who are optimally debulked.

Conclusion:  Our data suggest that aEOC patients with optimal cytoreduction who underwent SRL did not show a significant improvement in survival irrespective of each histological type.

Sunday, March 11, 2012

abstract: Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies



 Blogger's Note: the abstract does not differentiate types of gyn cancers, journal is subscriber based ($$$)

Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies

Objective 
Lymphatic ascites is an unusual complication in patients with cancer. In the gynecologic oncology patient population, the most common etiology is operative lymph node dissection. The purpose of this study was to explore the incidence, presenting symptoms, methods of diagnosis and treatment modalities utilized for lymphatic ascites in patients undergoing lymph node dissection for gynecologic cancers.

Methods 
This observational study retrospectively reviewed the charts of patients who underwent lymphadenectomy as part of the surgical management for a gynecologic cancer. Patients that developed postoperative lymphatic ascites between January 2000 and December 2010 were included for analysis. Data extracted from the medical records included tumor pathology, number of harvested lymph nodes, postoperative course, method of diagnosis and treatment.

Results
From a total of 300 surgical staging procedures, 12 patients with lymphatic ascites were identified (4%). The most common reported symptom was leakage of clear fluid per vagina (7, 58%), followed by abdominal distension (4, 33%). The median interval from surgery to development of symptoms was 12.5 days (range 0–22days). 5 patients had complete resolution of symptoms with dietary modifications alone while 7 patients required paracentesis. The median time from surgery to resolution of symptoms was 44days (range 9–99).

Conclusion 
Lymphatic ascites is an under recognized and infrequently reported postoperative complication. Although it usually resolves spontaneously or with conservative management without sequelae, this condition can significantly prolong postoperative recovery and cause patient discomfort. To our knowledge this is the largest group of patients undergoing gynecologic surgical staging procedures to be reviewed for the occurrence of lymphatic ascites.

Saturday, February 25, 2012

Postoperative lymphocysts after lymphadenectomy for gynaecological malignancies: preventive techniques and prospects



Postoperative lymphocysts after lymphadenectomy for gynaecological malignancies: preventive techniques and prospects

Postoperative lymphocyst formation is an insufficiently recognised complication of lymphadenectomy for gynaecological malignancies. Lymphocysts are collections of lymph organised into cysts that develop in contact with lymphadenectomy compartments.There has been considerable debate about the relevance of lymphocyst prevention using surgical (eg. surgical mesh/complications.....) or pharmacotherapeutic methods. Here, we review the available studies about the impact of these methods on the incidence of lymphocysts. This review suggests that several techniques may decrease the incidence of lymphocysts when used in combination. On a literature basis, the peritoneum should be left open over the lymphadenectomy sites at the end of the procedure and drains should not be placed at the end of the procedure (infection rates?) . Omentoplasty should be encouraged and further studies are needed to assess the potential benefits of new energies. Postoperative octreotide therapy seems beneficial but the role of this drug in pelvic oncological surgery remains to be determined.


Omentoplasty - o·men·to·plas·ty (-mnt-plst) n.

A surgical procedure in which a portion of the greater omentum is used to cover or fill a defect, augment arterial or portal venous circulation, absorb effusions, or increase lymphatic drainage.

Thursday, January 26, 2012

abstract: Lymph node metastasis in stages I and II ovarian cancer: a review.



CONCLUSIONS:

The incidence of lymph node metastases in clinical early stage EOC is considerable. Based on the scarce literature data, omitting a systematic lymphadenectomy can only be considered in grade I mucinous tumors.

Monday, August 22, 2011

abstract: Lymphadenectomy in ovarian cancer: standard of care or unne... : Current Opinion in Oncology



Abstract

Purpose of review: The clinical significance of lymphadenectomy in ovarian cancer is controversial. In early ovarian cancer (EOC), it is the extent of the procedure that is the main focus of debate. In advanced disease [advanced ovarian cancer (AOC)], the issue is whether or not lymphadenectomy independently impacts survival. This review summarizes the current standard of care as it relates to the role of lymphadenectomy in ovarian cancer.
Recent findings: Lymphadenectomy in EOC is a diagnostic procedure in as much as it is an integral and mandatory part of a complete surgical staging. The required extent of the procedure, however, remains uncertain. It has been suggested that at least 10 nodes from different, predefined retroperitoneal sites should be the minimum number removed. Lymphadenectomy in AOC is of potential therapeutic value. The only published randomized clinical trial (RCT) showed no overall survival benefit after radical/systematic lymphadenectomy, although there was an impact on 6-month disease-free survival. Conversely, retrospective studies, a meta-analysis and a re-analysis of three RCTs in AOC do suggest an overall survival benefit for radical/systematic lymphadenectomy.
Summary: This review concludes with the recommendation that lymphadenectomy in EOC is a mandatory part of surgical staging and that a minimum of 10 nodes should be harvested from different retroperitoneal sites. In AOC, lymphadenectomy can be considered when intraperitoneal cytoreduction has been complete or when there are bulky nodes.

Sunday, November 14, 2010

The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer



Abstract

AIM: The objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer.
CONCLUSION: This study has demonstrated that the systematic lymphadenectomy had benefit only in patients with ovarian cancer macroscopically confined to the pelvis. In patients with clear cell adenocarcinoma, systematic lymphadenectomy was beneficial. To the contrary, systematic lymphadenectomy had no benefit on OS or PFS in patients with advanced ovarian cancer if optimally debulked.

Thursday, July 29, 2010

Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary



Abstract

OBJECTIVE:: To estimate the prevalence of lymph node involvement in women with primary mucinous ovarian carcinomas.
METHODS:: A retrospective study was performed of patients with primary mucinous ovarian carcinomas evaluated at a single institution between 1985 and 2007. A gynecologic oncology pathologist evaluated all cases. Patients with tumors of low malignant potential and mucinous carcinomas metastatic to the ovary from other primary sites were excluded.
RESULTS:: Patients with primary mucinous ovarian carcinomas were identified (n=107). All patients underwent primary surgery. At time of surgery, 93 patients (87%) had tumors that grossly appeared to be confined to the ovary, and 14 patients (13%) had evidence of extraovarian disease. Of the 93 patients with tumors that grossly appeared to be confined to the ovary at surgical exploration, 51 (55%) underwent lymphadenectomy (n=27 pelvic and paraaortic, n=19 pelvic only, n=5 paraaortic only). Of these 51 patients, none had metastatic disease to the pelvic or paraaortic lymph nodes. In addition, there were no significant differences in progression-free survival and overall survival rates between the patients who underwent lymphadenectomy and those who did not.
CONCLUSION:: There were no cases of isolated lymph node metastases among women with primary mucinous carcinoma grossly confined to the ovary, suggesting that routine lymphadenectomy may be omitted in these patients.
LEVEL OF EVIDENCE:: III.
(link to 'levels of evidence': http://www.cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment

Wednesday, May 05, 2010

Systematic Lymphadenectomy for Survival in Epithelial Ovarian Cancer: A Meta-Analysis



Note: also see post of Dr Maurie Markman (blogger dat May 4th) for Editorial on this particular subject matter

Conclusions: These findings suggest the possibility that SL can improve OS in advanced-stage EOC. However, the efficacy of SL on OS is still unknown because of the lack of RCTs, which requires more relevant studies for investigating the role of SL in EOC

Tuesday, April 06, 2010

Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian Cancer



Conclusions: Based on diagnostic value, the result suggests that the role of lymphadenectomy might differ by histological type, as its therapeutic effect might be unclear. A multicenter analysis is essential for confirmation

Tuesday, March 30, 2010

Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials - Journal of Clinical Oncology



"Purpose:  Primary surgery followed by platinum/taxane-based chemotherapy is the standard therapy in advanced ovarian cancer. The prognostic role of complete debulking has been well described; however, the impact of systematic pelvic and para-aortic lymphadenectomy and its interaction with biologic factors are still not fully defined.
Conclusion:  Lymphadenectomy in advanced ovarian cancer might offer benefit mainly to patients with complete intraperitoneal debulking. However, this hypothesis should be confirmed in the context of a prospectively randomized trial."

Tuesday, March 02, 2010

Cochrane Review: Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with



Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies.

CONCLUSIONS: Placement of retroperitoneal tube drains has no benefit in prevention of lymphocyst formation after pelvic lymphadenectomy in patients with gynaecological malignancies. When the pelvic peritoneum is left open, the tube drain placement is associated with a higher risk of short and long-term symptomatic lymphocyst formation.

Wednesday, February 03, 2010

Cochrane Collaboration Review: Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies



Authors' conclusions:
Placement of retroperitoneal tube drains has no benefit in prevention of lymphocyst formation after pelvic lymphadenectomy in patients with gynaecological malignancies. When the pelvic peritoneum is left open, the tube drain placement is associated with a higher risk of short and long-term symptomatic lymphocyst formation.